Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Reduction of Bacterial Seeding in Total Shoulder Arthroplasty

NCT07406893 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to compare the growth of intra-operative tissue cultures of Cutibacterium Acnes after primary shoulder replacement when using a no-prep control group versus Prontosan wound gel applied to the skin layer after the skin incision has been made.

Interventions

  • DEVICE Prontosan Wound Gel

Study Locations (1)

Missouri

  • Saint Louis University — St Louis

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2026-02-23
Est. Completion 2026-12
Phase NA

Sponsor

St. Louis University

35 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07406893

The ClinicalTrials.gov registry entry for NCT07406893 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Louis University, which has 35 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Shoulder appearing as the primary indexed condition, and to 1 intervention — of which Prontosan Wound Gel is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07406893 reports 1 study location spanning 1 distinct geographic area — top geographies include Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07406893 about?

NCT07406893 is a clinical study titled "Reduction of Bacterial Seeding in Total Shoulder Arthroplasty". The purpose of this study is to compare the growth of intra-operative tissue cultures of Cutibacterium Acnes after primary shoulder replacement when using a no-prep control group versus Prontosan wound gel applied to the skin layer after the skin incision has been made.

What is the current status of trial NCT07406893?

This trial is currently recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2026-02-23. Estimated completion is 2026-12.

What conditions does trial NCT07406893 study?

This clinical trial studies the following conditions: Shoulder, Prosthetic Joint Infection, Cutibacterium Acnes, Joint Arthroplasty. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07406893?

The interventions under investigation include: Prontosan Wound Gel (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07406893?

This trial is sponsored by St. Louis University, which has 35 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07406893 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial